J&J, Pharmacyclics celebrate yet another nod for leukemia med Imbruvica

Tracy Staton

Johnson & Johnson's new blood cancer drug  (ibrutinib) is on a roll. The FDA just armed the drug with a new indication in chronic lymphocytic , adding to a series of regulatory nods.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS